Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a 10BSH-containing WOW emulsion

• We started the pilot clinical study of BNCT to recurrence hepatic cancer.
• The tumor size was remained stable during 3 months after BNCT(SD).
• No adverse effect as a result of BNCT was observed during follow-up period.
• 10B-containing WOW emulsion can be applied as a novel intra-arterial boron carrier for BNCT for HCC.

A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a 10BSH-containing water-in-oil-in-water emulsion (10BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that 10BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.